Lack of association of the 5-HT3A receptor with schizophrenia

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 159 B, Issue 3, 2012, Pages 310-315

  Nothdurfter, Caroline ^a,b   Giegling, Ina ^c   Konte, Bettina ^c   Hartmann, Annette M ^c   Konnerth, Heike ^c   Friedl, Marion ^c   Rammes, Gerhard ^b,d   Rupprecht, Rainer ^a,b   Rujescu, Dan ^c  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

5 HT3A receptor; Clozapine; Genotyping; Schizophrenia; SNP

Indexed keywords

SEROTONIN 3A RECEPTOR;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; CASE-CONTROL STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, SEROTONIN, 5-HT3; SCHIZOPHRENIA;

EID: 84857988947     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.32028     Document Type: Article

References (33)

1. Abi-Dargham A, Moore H. 2003. Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 9: 404- 416.
2. Adler LE, Cawthra EM, Donovan KA, Harris JG, Nagamoto HT, Olincy A, Waldo MC. 2005. Improved p50 auditory gating with ondansetron in medicated schizophrenia patients. Am J Psychiatry 162: 386- 388.
3. Akhondzadeh S, Mohammadi N, Noroozian M, Karamghadiri N, Ghoreishi A, Jamshidi AH, Forghani S. 2009. Added ondansetron for stable schizophrenia: A double blind, placebo controlled trial. Schizophr Res 107: 206- 212.
4. Awad AG, Voruganti LN. 2008. The burden of schizophrenia on caregivers: A review. Pharmacoeconomics 26: 149- 162.
5. Barnes NM, Sharp T. 1999. A review of central 5-HT receptors and their function. Neuropharmacology 38: 1083- 1152.
6. Bertolino A, Blasi G. 2009. The genetics of schizophrenia. Neuroscience 164: 288- 299.
7. Brunello N, Masotto C, Steardo L, Markstein R, Racagni G. 1995. New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 13: 177- 213.
8. Cockrell JR, Folstein MF. 1988. Mini-Mental State Examination (MMSE). Psychopharmacol Bull 24: 689- 692.
9. Fletcher S, Barnes NM. 1998. Desperately seeking subunits: Are native 5-HT3 receptors really homomeric complexes? Trends Pharmacol Sci 19: 212- 215.
10. Gu B, Wang L, Zhang AP, Ma G, Zhao XZ, Li HF, Feng GY, He L, Xing QH. 2008. Association between a polymorphism of the HTR3A gene and therapeutic response to risperidone treatment in drug-naive Chinese schizophrenia patients. Pharmacogenet Genomics 18: 721- 727.
11. Hannon J, Hoyer D. 2008. Molecular biology of 5-HT receptors. Behav Brain Res 195: 198- 213.
12. Heinz A, Schlagenhauf F. 2010. Dopaminergic dysfunction in schizophrenia: Salience attribution revisited. Schizophr Bull 36: 472- 485.
13. Hussy N, Lukas W, Jones KA. 1994. Functional properties of a cloned 5-hydroxytryptamine ionotropic receptor subunit: Comparison with native mouse receptors. J Physiol 481(Pt 2): 311- 323.
14. Ibrahim HM, Tamminga CA. 2011. Schizophrenia: Treatment targets beyond monoamine systems. Annu Rev Pharmacol Toxicol 51: 189- 209.
15. Ji X, Takahashi N, Saito S, Ishihara R, Maeno N, Inada T, Ozaki N. 2008. Relationship between three serotonin receptor subtypes (HTR3A, HTR2A and HTR4) and treatment-resistant schizophrenia in the Japanese population. Neurosci Lett 435: 95- 98.
16. Kuroki T, Nagao N, Nakahara T. 2008. Neuropharmacology of second-generation antipsychotic drugs: A validity of the serotonin-dopamine hypothesis. Prog Brain Res 172: 199- 212.
17. Levkovitz Y, Arnest G, Mendlovic S, Treves I, Fennig S. 2005. The effect of ondansetron on memory in schizophrenic patients. Brain Res Bull 65: 291- 295.
18. Luna A, Nicodemus KK. 2007. snp.plotter: An R-based SNP/haplotype association and linkage disequilibrium plotting package. Bioinformatics 23: 774- 776.
19. Maricq AV, Peterson AS, Brake AJ, Myers RM, Julius D. 1991. Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel. Science 254: 432- 437.
20. Mylecharane EJ. 1996. Ventral tegmental area 5-HT receptors: Mesolimbic dopamine release and behavioural studies. Behav Brain Res 73: 1- 5.
21. Niesler B, Weiss B, Fischer C, Nöthen MM, Propping P, Bondy B, Rietschel M, Maier W, Albus M, Franzek E, Rappold GA. 2001. Serotonin receptor gene HTR3A variants in schizophrenic and bipolar affective patients. Pharmacogenetics 11: 21- 27.
22. Rammes G, Rupprecht R. 2007. Modulation of ligand-gated ion channels by antidepressants and antipsychotics. Mol Neurobiol 35: 160- 174.
23. Rammes G, Eisensamer B, Ferrari U, Shapa M, Gimpl G, Gilling K, Parsons C, Riering K, Hapfelmeier G, Bondy B, Zieglgänsberger W, Holsboer F, Rupprecht R. 2004. Antipsychotic drugs antagonize human serotonin type 3 receptor currents in a noncompetitive manner. Mol Psychiatry 9: 846- 858, 818.
24. Rammes G, Hosp C, Eisensamer B, Tanasic S, Nothdurfter C, Zieglgänsberger W, Rupprecht R. 2009. Identification of a domain which affects kinetics and antagonistic potency of clozapine at 5-HT3 receptors. PLoS ONE 4: e6715.
25. Reeves DC, Lummis SC. 2006. Detection of human and rodent 5-HT3B receptor subunits by anti-peptide polyclonal antibodies. BMC Neurosci 7: 27.
26. Rice JP, Reich T, Bucholz KK, Neuman RJ, Fishman R, Rochberg N, Hesselbrock VM, Nurnberger JI, Jr., Schuckit MA, Begleiter H. 1995. Comparison of direct interview and family history diagnoses of alcohol dependence. Alcohol Clin Exp Res 19: 1018- 1023.
27. Sayed Y, Garrison JM. 1983. The dopamine hypothesis of schizophrenia and the antagonistic action of neuroleptic drugs-A review. Psychopharmacol Bull 19: 283- 288.
28. Schuhmacher A, Mössner R, Quednow BB, Kühn KU, Wagner M, Cvetanovska G, Rujescu D, Zill P, Möller HJ, Rietschel M, Franke P, Wölwer W, Gaebel W, Maier W. 2009. Influence of 5-HT3 receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia. Pharmacogenet Genomics 19: 843- 851.
29. Souza RP, de Luca V, Meltzer HY, Lieberman JA, Kennedy JL. 2010. Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia. Pharmacogenet Genomics 20: 274- 276.
30. Spitzer RL, Williams JB, Gibbon M, First MB. 1992. The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. Arch Gen Psychiatry 49: 624- 629.
31. Stefansson H, Rujescu D, Cichon S, Pietilainen OP, Ingason A, Steinberg S, et al. 2008. Large recurrent microdeletions associated with schizophrenia. Nature 455: 232- 236.
32. van Hooft JA, Vijverberg HP. 2000. 5-HT(3) receptors and neurotransmitter release in the CNS: A nerve ending story? Trends Neurosci 23: 605- 610.
33. Williams JB, Gibbon M, First MB, Spitzer RL, Davies M, Borus J, et al. 1992. The Structured Clinical Interview for DSM-III-R (SCID). II. Multisite test-retest reliability. Arch Gen Psychiatry 49: 630- 636.